The shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been pegged with a rating of Neutral by Credit Suisse in its latest research note that was published on July 10th, 2019. Credit Suisse wasn’t the only research firm that published a report of Ironwood Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. Morgan Stanley advised investors in its research note published on March 27th, 2019, to Equal-Weight the IRWD stock. The stock had earned Neutral rating from H.C. Wainwright when it published its report on February 25th, 2019. That day the H.C. Wainwright set price target on the stock to $14. The stock was given Neutral rating by JP Morgan in its report released on January 24th, 2019. JP Morgan was of a view that IRWD is Underweight in its latest report on November 7th, 2018. Credit Suisse thinks that IRWD is worth Neutral rating. This was contained in the firm’s report on November 7th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 6 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $14.89. The price of the stock the last time has raised by 16.71% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 36.22.
The shares of the company dipped by -1.34% during the trading session on Thursday, reaching a low of $8.75 while ending the day at $8.86. During the trading session, a total of 1.58 million shares were traded which represents a -2.07% decline from the average session volume which is 1.55M shares. IRWD had ended its last session trading at 8.98. Ironwood Pharmaceuticals, Inc. currently has a market cap of $1.42B while its P/E earnings growth sits at 3.86, with a beta of 1.79. IRWD 52-week low price stands at $7.59 while its 52-week high price is $16.44.
The company in its last quarterly report recorded -$0.26 earnings per share which is below the -$0.14 predicted by most analysts. The Ironwood Pharmaceuticals, Inc. generated $68.73 million in revenue during the last quarter, which is slightly lower than the $82.29 million predicted by analysts. In the second quarter last year, the firm recorded -$0.02 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 92.31%. Ironwood Pharmaceuticals, Inc. has the potential to record -1.30 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Credit Suisse published a research note on August 7th, 2019 where it informed investors and clients that WEC Energy Group, Inc. (NYSE:WEC) is now rated as Underperform. Morgan Stanley also rated WEC as Upgrade on March 27th, 2019, with its price target of $7 suggesting that WEC could down by -8.64% from its current share price. Even though the stock has been trading at $92.74/share, analysts expect it to surge higher by 0.43% to reach $85.73/share. It started the day trading at $93.29 and traded between $92.18 and $93.14 throughout the trading session.
A look at its technical shows that WEC’s 50-day SMA is 86.73 while its 200-day SMA stands at 78.04. The stock has a high of $92.78 for the year while the low is $64.96. The company’s P/E ratio currently sits at 26.97, while the P/B ratio is 2.93. At the moment, only of WEC Energy Group, Inc. shares were sold short. The company’s average trading volume currently stands at 1.68M shares, which means that the short-interest ratio is just 6.95 days. Over the past seven days, the company moved, with its shift of 2.70%. Looking further, the stock has raised 13.27% over the past 90 days while it gained 21.53% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more WEC shares, increasing its portfolio by +1.77% during the last quarter. This move now sees The Vanguard Group Inc purchasing 675,199 shares in the last quarter, thus it now holds 38,867,464 shares of WEC, with a total valuation of $3,321,613,473. BlackRock Fund Advisors meanwhile bought more WEC shares in the recently filed quarter, changing its stake to $1,879,741,412 worth of shares. SSgA Funds Management Inc followed the path by increasing its WEC portfolio by +1.30% in the quarter. This means that SSgA Funds Management Inc bought 213,419 shares in the last quarter and now controls 16,615,040 shares of the WEC stock, with the valuation hitting $1,419,921,318.
Similarly, Magellan Asset Management Ltd increased its WEC Energy Group, Inc. shares by +456.91% during the recently filed quarter. After buying 5,600,357 shares in the last quarter, the firm now controls 6,826,069 shares of WEC Energy Group, Inc. which are valued at $583,355,857. In the same vein, JPMorgan Investment Management I increased its WEC Energy Group, Inc. shares by during the most recent reported quarter. The firm bought 5,610 shares during the quarter which increased its stakes to 5,749,135 shares and is now valued at $491,321,077. Following these latest developments, around 0.10% of WEC Energy Group, Inc. stocks are owned by institutional investors and hedge funds.